keyword
MENU ▼
Read by QxMD icon Read
search

Metastatic

keyword
https://www.readbyqxmd.com/read/29783185/impact-of-body-mass-index-on-the-efficacy-of-endocrine-therapy-in-patients-with-metastatic-breast-cancer-a-retrospective-two-center-cohort-study
#1
Luwam Zewenghiel, Henrik Lindman, Antonis Valachis
BAKGROUND: The aim of this study was to investigate the impact of body mass index (BMI) on the efficacy of endocrine therapy in postmenopausal women with metastatic hormone receptor breast cancer (HR+BC) as well as to identify if the potential difference in efficacy was associated with Fulvestrant only or both aromatase inhibitors (AIs) and Fulvestrant. METHODS: A consecutive cohort of postmenopausal women with HR+metastatic breast cancer that have received endocrine therapy including Fulvestrant as a metastatic treatment strategy at the Departments of Oncology in Eskilstuna and Uppsala, Sweden, between 2008 and 2016 were identified...
May 18, 2018: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/29783001/laparoscopic-extraperitoneal-pelvic-lymph-node-debulking-in-locally-advanced-cervical-cancer
#2
Diaz-Feijoo Berta, Luna-Guibourg Rocio, Cabrera Silvia, Manrique Susana, Gil-Moreno Antonio
OBJECTIVE: To demonstrate the feasibility of laparoscopic extraperitoneal approach for pelvic metastatic lymph node debulking in locally advanced cervical cancer. DESIGN: Surgical video article. Canadian task force Classification III. SETTING: University Hospital PATIENT: A 52 year-old patient presented a stage IIA2 Cervical adenocarcinoma according to FIGO classification. The physical exam reported a 45 mm tumor. Positron emission tomography (PET- CT) was positive for hypermetabolic enlarged lymph nodes in left external iliac region of 1...
May 18, 2018: Journal of Minimally Invasive Gynecology
https://www.readbyqxmd.com/read/29782872/oxyfadichalcone-c-inhibits-melanoma-a375-cell-proliferation-and-metastasis-via-suppressing-pi3k-akt-and-mapk-erk-pathways
#3
Xiaolin Peng, Zhengming Wang, Yang Liu, Xin Peng, Yao Liu, Shan Zhu, Zhe Zhang, Yuling Qiu, Meihua Jin, Ran Wang, Qingying Zhang, Dexin Kong
AIMS: Melanoma remains to be one of the most incurable cancers. Discovery of novel antitumor agent for melanoma therapy is expected. We recently isolated Oxyfadichalcone C from Oxytropis falcate and investigated the anti-proliferative and anti-metastatic activity on human melanoma A375 cells in vitro. MAIN METHODS: Cell viability was determined using MTT assay and soft agar cloning formation assay. The effect of Oxyfadichalcone C on cell cycle distribution and apoptosis were analyzed by flow cytometry...
May 18, 2018: Life Sciences
https://www.readbyqxmd.com/read/29782606/-68-ga-psma-and-11-c-choline-comparison-using-a-tri-modality-pet-ct-mri-3-0-t-system-with-a-dedicated-shuttle
#4
Omar Alonso, Gerardo Dos Santos, Margarita García Fontes, Henia Balter, Henry Engler
Background: The aim of this study was to prospectively compare the detection rate of 68 Ga-PSMA versus 11 C-Choline in men with prostate cancer with biochemical recurrence and to demonstrate the added value of a tri-modality PET/CT-MRI system. Methods: We analysed 36 patients who underwent both 11 C-Choline PET/CT and 68 Ga-PSMA PET/CT scanning within a time window of 1-2 weeks. Additionally, for the 68 Ga-PSMA scan, we used a PET/CT-MRI (3.0 T) system with a dedicated shuttle, acquiring MRI images of the pelvis...
2018: Eur J Hybrid Imaging
https://www.readbyqxmd.com/read/29782572/patient-related-outcomes-with-the-use-of-checkpoint-inhibitors-for-the-treatment-of-metastatic-non-small-cell-lung-cancer
#5
EDITORIAL
Jyoti Malhotra, Salma K Jabbour
No abstract text is available yet for this article.
April 2018: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/29782499/tgf%C3%AE-signaling-limits-lineage-plasticity-in-prostate-cancer
#6
Yi Hao, Glen A Bjerke, Karolina Pietrzak, Tiffany A Melhuish, Yu Han, Stephen D Turner, Henry F Frierson, David Wotton
Although treatment options for localized prostate cancer (CaP) are initially effective, the five-year survival for metastatic CaP is below 30%. Mutation or deletion of the PTEN tumor suppressor is a frequent event in metastatic CaP, and inactivation of the transforming growth factor (TGF) ß signaling pathway is associated with more advanced disease. We previously demonstrated that mouse models of CaP based on inactivation of Pten and the TGFß type II receptor (Tgfbr2) rapidly become invasive and metastatic...
May 21, 2018: PLoS Genetics
https://www.readbyqxmd.com/read/29782466/mucin-expression-in-colorectal-cancer-crc-systematic-review-and-meta-analysis
#7
Yaron Niv, Theodore Rokkas
BACKGROUND: A body of evidence has suggested that mucins play an important role in adhesion, invasion, and cancer metastasis. However, this evidence is scarce and sometimes confusing. OBJECTIVE: We performed a systematic review and meta-analysis of available studies to better define the role of mucins in the behavior of colorectal cancer (CRC). METHODS: Medical literature was searched through November 30, 2017, using suitable keywords. Pooled estimates, that is, odd ratios (ORs), were obtained using fixed or random-effects models, as appropriate...
May 18, 2018: Journal of Clinical Gastroenterology
https://www.readbyqxmd.com/read/29782393/clinical-and-prognostic-value-of-18f-fdg-pet-ct-in-restaging-of-pancreatic-cancer
#8
Domenico Albano, Demetrio Familiari, Roberta Gentile, Salvatore Scalisi, Federico Midiri, Marco Messina, Massimiliano Spada, Maria C Fornito, Massimo Galia, Massimo Midiri, Pierpaolo Alongi
AIM: The aim of this retrospective multicentre study was to evaluate the clinical and prognostic effect of fluorine-18-fluorodeoxyglucose (F-FDG)-PET/computed tomography (CT) in the restaging process of pancreatic cancer (PC). MATERIALS AND METHODS: Data from patients treated for primary PC, who underwent F-FDG-PET/CT for suspicious of disease progression, were collected. Accuracy was assessed employing conventional diagnostic procedures, multidisciplinary team case notes, further F-FDG-PET/CT scans and/or follow-up...
May 18, 2018: Nuclear Medicine Communications
https://www.readbyqxmd.com/read/29782381/high-baseline-neutrophil-to-lymphocyte-ratio-predicts-worse-outcome-in-patients-with-metastatic-braf-positive-melanoma-treated-with-braf-and-mek-inhibitors
#9
Paweł Teterycz, Paulina Jagodzińska-Mucha, Bożena Cybulska-Stopa, Anna Mariuk-Jarema, Katarzyna Kozak, Hanna Koseła-Paterczyk, Anna M Czarnecka, Marcin Rajczykowski, Robert Dziura, Łukasz Galus, Jacek Mackiewicz, Tomasz Świtaj, Anna Klimczak, Slawomir Falkowski, Rafał Suwiński, Marek Ziobro, Iwona Ługowska, Piotr Rutkowski
Neutrophil-to-lymphocyte ratio (NLR) has been shown to be prognostic in several solid malignancies. There are limited data regarding its value during novel therapies in patients with melanoma. The aim of the study was to assess the practical utility of this ratio in patients with BRAF-mutant melanoma treated with a combination of BRAF and MEK inhibitors (BRAFi/MEKi). We included 215 patients with inoperable or metastatic melanoma who underwent BRAFi/MEKi treatment between October 2015 and June 2017. Baseline NLR and other complete blood count-derived inflammatory markers were tested for association with overall survival and progression-free survival in univariate and multivariate models...
May 18, 2018: Melanoma Research
https://www.readbyqxmd.com/read/29782361/the-significance-of-para-aortic-nodal-size-and-the-role-of-adjuvant-systemic-chemotherapy-in-cervical-cancer-an-institutional-experience
#10
Dustin B Manders, Travis T Sims, April Bailey, Lindsay Hwang, Debra L Richardson, David S Miller, Siobhan M Kehoe, Kevin V Albuquerque, Jayanthi S Lea
OBJECTIVE: Cervical cancer metastatic to the para-aortic lymph nodes (PALNs) carries a poor prognosis. Despite extended-field radiation therapy (EFRT), only 30% to 50% of patients will survive 3 years. We sought to examine the treatment regimens used, associated toxicities, and treatment outcomes in patients with cervical cancer metastatic to PALN. METHODS: A retrospective review was performed of all patients with cervical cancer treated at a single institution between January 1, 2007 and November 1, 2014...
May 18, 2018: American Journal of Clinical Oncology
https://www.readbyqxmd.com/read/29782360/a-phase-ii-study-of-celecoxib-with-irinotecan-5-fluorouracil-and-leucovorin-in-patients-with-previously-untreated-advanced-or-metastatic-colorectal-cancer
#11
Emerson Y Chen, Charles D Blanke, Daniel G Haller, Al B Benson, Tomislav Dragovich, Heinz-Josef Lenz, Carlos Robles, Hong Li, Motomi Mori, Nora Mattek, Rachel E Sanborn, Charles D Lopez
OBJECTIVE: Colorectal cancer (CRC) is the second leading cause of cancer death in the United States. Cyclooxygenase-2 (COX-2) overexpression is associated with increased tumor invasiveness and proliferation in CRC, and COX-2 inhibition has demonstrated chemopreventive activity. This study investigated the addition of celecoxib, a selective COX-2 inhibitor, to the irinotecan, 5-fluorouracil, and leucovorin (IFL) regimen for patients with previously untreated metastatic CRC. PATIENTS AND METHODS: Forty-seven patients enrolled in this single-arm phase II study received celecoxib at 400 mg orally twice daily in combination with weekly irinotecan (125 mg/m), 5-fluorouracil (500 mg/m), and leucovorin (20 mg/m) for 4 weeks every 6 weeks...
May 18, 2018: American Journal of Clinical Oncology
https://www.readbyqxmd.com/read/29782352/an-update-on-the-management-of-pancreatic-neuroendocrine-tumors
#12
Limin Gao, Nikola S Natov, Kevin P Daly, Faisal Masud, Sadia Chaudhry, Mark J Sterling, Muhammad W Saif
Pancreatic neuroendocrine tumors (PNETs) are a rare and heterogeneous group of neoplasia and differ in their clinical presentation, behavior, and prognosis based on both histological features and cancer stage at the time of diagnosis. Although small-sized tumors can be surgically resected, locally advanced and metastatic tumors confer a poor prognosis. In addition, only limited treatment options are available to the latter group of patients with PNETs, such as hormonal analogs, cytotoxic agents, and targeted therapy...
May 8, 2018: Anti-cancer Drugs
https://www.readbyqxmd.com/read/29782348/renal-ewing-sarcoma-treated-with-apatinib
#13
Yang Zhao, Ye Chen, Ke Cheng, Zhi-Ping Li, Hao Zeng, Ji-Yan Liu
Renal Ewing sarcoma (RES) is an extremely rare disease. The standard treatment for this disease is lacking, and clinical experience needs to be accumulated. Here, we report a case of RES that rapidly developed to metastatic disease and was refractory to radiotherapy and chemotherapy; however, the case obtained a partial response based on Choi criteria by orally taking antiangiogenic drug apatinib. Our case suggests that apatinib may be a therapeutic option for RES.
May 18, 2018: Anti-cancer Drugs
https://www.readbyqxmd.com/read/29782246/precision-medicine-and-radiogenomics-in-breast-cancer-new-approaches-toward-diagnosis-and-treatment
#14
Katja Pinker, Joanne Chin, Amy N Melsaether, Elizabeth A Morris, Linda Moy
Precision medicine is medicine optimized to the genotypic and phenotypic characteristics of an individual and, when present, his or her disease. It has a host of targets, including genes and their transcripts, proteins, and metabolites. Studying precision medicine involves a systems biology approach that integrates mathematical modeling and biology genomics, transcriptomics, proteomics, and metabolomics. Moreover, precision medicine must consider not only the relatively static genetic codes of individuals, but also the dynamic and heterogeneous genetic codes of cancers...
June 2018: Radiology
https://www.readbyqxmd.com/read/29782188/an-evaluation-of-nivolumab-for-the-treatment-of-metastatic-renal-cell-carcinoma
#15
Kevin Zarrabi, Shenhong Wu
The treatment paradigm for metastatic renal cell carcinoma (mRCC) has undergone a revolution with the rapid market approval of multiple agents over a three-year period. The immunogenicity of RCC provided the biological rationale to assess the clinical efficacy of nivolumab, an immune checkpoint inhibitor. Nivolumab is approved for second-line treatment after failure of angiogenesis targeted therapy and in combination therapy with ipilimumab for previously untreated intermediate or poor-risk advanced renal cell carcinoma...
May 21, 2018: Expert Opinion on Biological Therapy
https://www.readbyqxmd.com/read/29782011/a-preclinical-mouse-model-of-osteosarcoma-to-define-the-extracellular-vesicle-mediated-communication-between-tumor-and-mesenchymal-stem-cells
#16
Tonny Lagerweij, Maria Pérez-Lanzón, S Rubina Baglio
Within the tumor microenvironment, resident or recruited mesenchymal stem cells (MSCs) contribute to malignant progression in multiple cancer types. Under the influence of specific environmental signals, these adult stem cells can release paracrine mediators leading to accelerated tumor growth and metastasis. Defining the crosstalk between tumor and MSCs is of primary importance to understand the mechanisms underlying cancer progression and identify novel targets for therapeutic intervention. Cancer cells produce high amounts of extracellular vesicles (EVs), which can profoundly affect the behavior of target cells in the tumor microenvironment or at distant sites...
May 6, 2018: Journal of Visualized Experiments: JoVE
https://www.readbyqxmd.com/read/29781860/utility-of-immunohistochemistry-in-distinguishing-primary-adnexal-carcinoma-from-metastatic-breast-carcinoma-to-skin-and-squamous-cell-carcinoma
#17
Aida Valencia-Guerrero, Karen Dresser, Kristine M Cornejo
The distinction between primary adnexal carcinoma (PAC) from metastatic breast carcinoma (BrCa) to skin and squamous cell carcinoma (SCC), particularly those with ductal differentiation (SCCDD), can be quite challenging, despite adequate history. The aim of the study was to determine the utility of an immunohistochemistry (IHC) panel to differentiate these entities and apply them to ambiguous tumors. Twenty-seven PAC, 7 metastatic BrCa, 28 SCC, and 16 ambiguous cases (SCCDD vs. PAC, n = 13 and metastatic BrCa vs...
June 2018: American Journal of Dermatopathology
https://www.readbyqxmd.com/read/29781575/brn2-a-pouerful-driver-of-melanoma-phenotype-switching-and-metastasis
#18
REVIEW
Mitchell E Fane, Yash Chhabra, Aaron G Smith, Richard A Sturm
The POU domain family of transcription factors play a central role in embryogenesis and are highly expressed in neural crest cells and the developing brain. BRN2 is a class III POU domain protein that is a key mediator of neuroendocrine and melanocytic development and differentiation. While BRN2 is a central regulator in numerous developmental programs, it has also emerged as a major player in the biology of tumourigenesis. In melanoma, BRN2 has been implicated as one of the master regulators of the acquisition of invasive behavior within the phenotype-switching model of progression...
May 21, 2018: Pigment Cell & Melanoma Research
https://www.readbyqxmd.com/read/29781364/pet-ct-analysis-of-21-patients-with-breast-cancer-physiological-distribution-of-18-f-choline-and-diagnostic-pitfalls
#19
Fathinul Fikri Ahmad Saad, Mohd Hazeman Zakaria, Bahunu Appanna
Objectives 18 F-choline is a useful tracer for detecting tumours with high lipogenesis. Knowledge of its biodistribution pattern is essential to recognise physiological variants. The aim of this study was to describe the physiologic distribution of 18 F-choline and pitfalls in patients with breast cancer. Methods Twenty-one consecutive patients with breast cancer (10 premenopausal and 11 postmenopausal women; mean age, 52.82 ± 10.71 years) underwent 18 F-choline positron emission tomography (PET)/computed tomography (CT) for staging...
January 1, 2018: Journal of International Medical Research
https://www.readbyqxmd.com/read/29781343/issues-and-promises-of-bevacizumab-in-prostate-cancer-treatment
#20
Vittore Cereda, Vincenzo Formica, Mario Roselli
There is general agreement that increased angiogenesis is an important factor in determining prostate cancer development and prognosis. Vascular Endothelial Growth Factor (VEGF) is thought to play a primary role in the molecular events that lead to prostate cancer progression, from androgen-dependency to castration-resistance until dissemination to the skeleton. Bevacizumab is a recombinant anti-VEGF monoclonal antibody that has exhibited clinical activity in different cancer types. Areas covered: In this review we summarize the data of clinical trials, investigating the effects of bevacizumab in prostate cancer patients...
May 21, 2018: Expert Opinion on Biological Therapy
keyword
keyword
36941
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"